<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00243321</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-02961</org_study_id>
    <nct_id>NCT00243321</nct_id>
  </id_info>
  <brief_title>High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer</brief_title>
  <official_title>Phase I Examination of Combination High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Therapy for the Comprehensive Local Treatment of Patients With Locally Confined Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal objective of this study is to demonstrate that patients can safely receive
      combined High Dose Rate brachytherapy and Intensity-Modulated Radiation Therapy without
      experiencing a treatment limiting toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive a single High Dose Rate brachytherapy dose of 6 Gy to the prostate,
      followed by 61 Gy delivered to the prostate and nearby tissues using Intensity-Modulated
      Radiation Therapy in 28 treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate that patients can safely receive combined HDR brachytherapy and IMRT teletherapy to a total dose consistent with current treatment policies and without experiencing a treatment limiting toxicity</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <arm_group>
    <arm_group_label>HDR brachytherapy -&gt; IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high dose-rate brachytherapy</intervention_name>
    <description>High dose-rate brachytherapy</description>
    <arm_group_label>HDR brachytherapy -&gt; IMRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>intensity-modulated radiation therapy</description>
    <arm_group_label>HDR brachytherapy -&gt; IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TRUS biopsy proven adenocarcinoma of the prostate Pretreatment PSA &lt;30 ng/ml Gleason's
             sum &lt; 8 clinical stage T1 or T2a,b. patients that are at low-intermediate risk for
             disease beyond the prostate normal liver function for all patients beginning hormone
             therapy Karnofsky Performance score &gt; 80 acceptable anesthesia risk as determined
             through routine pre-operative screening in the VCUHS Diagnostic Testing Clinic

        Exclusion Criteria:

          -  pubic-arch interference or regional disease ( no evidence of metastatic disease for
             patients whose PSA is greater than 10 ng/ml, Gleason's sum is greater than 6, or
             T-stage is greater than T2a.

        Patients at high risk for distant disease (PSA &gt; 30 ng/ml, Gleason's sum &gt; 8 or clinical
        stage &gt; T2c), clinically involved seminal vesicles or extension beyond the prostate capsule
        history of inflammatory bowel disease require steroid or cytotoxic therapy for collagen
        vascular disease uncontrolled or poorly controlled hypertension uncontrolled or poorly
        controlled diabetes mellitus history of cancer other than skin cancer within five years of
        the initiation of protocol treatment history of pelvic irradiation require the routine use
        of warfarin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Hagan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Amer AM, Mott J, Mackay RI, Williams PC, Livsey J, Logue JP, Hendry JH. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):199-207.</citation>
    <PMID>12694839</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2005</study_first_submitted>
  <study_first_submitted_qc>October 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2005</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brachytherapy</keyword>
  <keyword>intensity-modulated radiation therapy</keyword>
  <keyword>prostate specific antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

